Chemical Conization of Cervical Precancerous Lesions

Awakening immune cells to restore normal, HPV-negative epithelium — without a scalpel.

A Chemical Alternative to Surgical Conization

Persistent infection with high-risk human papillomavirus (HPV) is a leading cause of cervical cancer. Current treatment relies on radical hysterectomy, radiotherapy, and chemotherapy — or surgical cervical conization.

Our compound formulation (UMPIC) is injected at four points around the cervix (12, 3, 6, and 9 o'clock positions, 0.5ml each) under direct visualization. The resulting local epithelial inflammation, immune response, and epithelial shedding trigger regeneration and repair — achieving the same clinical goal as surgical conization without cutting tissue.

In a single-cell RNA sequencing study (40,239 cells) comparing biopsies before and roughly one week after treatment, hapten-enhanced intratumoral chemotherapy (HEIC) induced an acute immune response in precancerous cervical lesions — restoring normal, HPV-negative tissue.

Chemical conization mechanism

Why Chemical Conization

Tissue-Preserving

Avoids the tissue loss, bleeding, and cervical incompetence risk associated with surgical conization — important for women who may still wish to bear children.

HPV Clearance

Induces an immune response that drives lesions toward HPV-negative status, not just physical tissue removal.

Outpatient Procedure

Performed in the office under direct visualization, following the same disinfection and exposure steps as conventional conization — without the cone incision.

Back to Technologies